CPVT-Associated Variants in Whole-Exome Sequencing
for ≈50% to 60% of cases. 3 Classically, these mutations affect a single amino acid (missense) and are associated with autosomal dominant pattern of disease inheritance. Pathological mutations cause leakage of Ca 2+ stored within the sarcoplasmic reticulum (so-called store Ca 2+ ) into the cytosol, particularly during sympathetic stimulation. This store Ca 2+ leak triggers delayed afterdepolarization and Ca 2+ overload-induced VT and ventricular fibrillation. RYR2 is one of the largest genes in the human genome, containing 105 coding exons, and clinical genetic testing has traditionally been focused on 3 hotspot domains. Recently, genetic evaluation of RYR2 has broadened to encompass the entire coding sequence of this gene. Although this offers an expanded ability to identify clinically relevant biomarkers, there is a paucity of understanding on the background genetic variation inherent in the gene. 5 A second genetic subtype of CPVT is CASQ2-encoded calsequestrin 2 (Casq2) which accounts for a minority of CPVT cases. 6 Mutations in this 11 exon gene have been widely linked to the pathogenesis of RYR2-negative CPVT and are classically inherited in an autosomal recessive manner. In addition, rare causes of CPVT have been associated with mutations in TRDN-encoded triadin (Trdn) and CALM1-encoded calmodulin type 1 (Calm1) which account for ≈1% of CPVT-associated mutations. 7 To this end, we systematically evaluated a large database of WES report genetic variants and compared it to a large cohort of ostensibly healthy control individuals and clinically robust cases of CPVT. We describe the spectrum and prevalence of genetic variation within RYR2 and CASQ2 among individuals undergoing WES testing, and demonstrate statistical similarities between WES genetic variation and healthy background variation.
Methods

Study Cohorts
The study included 4 cohorts. The clinical WES cohort (also referred to as the referral cohort) comprised individuals referred for genetic testing to the Baylor Miraca Genetics Laboratories (Houston, TX; previously Baylor College of Medicine Medical Genetics Laboratories) independent of referral diagnosis or indication for genetic testing. Demographic and clinical referral information was abstracted. Genetic information from samples derived for platform validation studies, or from oncological samples, was excluded. Probands, and biological parents of probands in so-called trio studies, were included to maximize the ability to detect variants. Variants included in this study were (1) identified in the coding nucleotide sequence, or predicted splice junction, of RYR2 or CASQ2, (2) deemed likely pathological or VUS at the time of genetic testing, (3) included on the clinical report sent to the referring provider or an expanded reported provided to the clinician on request, and (4) heterozygous mutations in CASQ2 were included that were deemed likely pathological or VUSs. Because of the low frequency of TRDN and CALM1 mutations among patients with CPVT, these genes were not analyzed. Variants excluded from this study were (1) interpreted as not pathogenic at the time of genetic testing or (2) synonymous variants.
The CPVT case cohort was based on a compendium established in the literature as previously described. 8 This cohort consisted of 155 individuals clinically diagnosed with CPVT. Among this cohort, 33 were deemed clinically robust, who demonstrated exertional syncope and documented biventricular or polymorphic VT. Individuals with a possible CPVT diagnosis demonstrated exertional syncope and stress test-induced ventricular ectopy without VT.
The control cohort comprised genetic findings derived from the ExAC database which consisted of individuals of African/Black (N=5203), Latino (N=5789), East Asian (N=4327), Finnish (N=3307), Non-Finnish European (N=33 370), South Asian (N=8256), and other individuals (N=454) for a total of 60 706 largely ostensibly healthy individuals. 9 Genetic variants associated with RYR2 and CASQ2 with a minor allele frequency <0.01 were included.
The Texas Children's Hospital (TCH) cohort comprised individuals within the clinical WES cohort who hosted rare variants in RYR2 and CASQ2 who were referred from TCH, Baylor College of Medicine (Houston, TX). These individuals were identified based on referral records and cross-referencing with clinical records. Anonymous clinical information, including basic demographics, clinical evaluation and diagnoses, 12-lead ECG, 24-hour Holter, cardiac stress test, and transthoracic echocardiographic findings, was reviewed retrospectively and abstracted when available. Patients referred for evaluation by pediatric cardiology were noted, and all records were reviewed for clinical suspicion, or diagnosis, of CPVT. This research study was approved by the Baylor College of Medicine Institutional Review Board.
Whole-Exome Sequencing
From October 2011 through October 2015, clinical WES was completed in the Exome Laboratory at Baylor Miraca Genetics Laboratories, and sequencing and data analyses were conducted as previously described. 10 Extracted DNA, subjected to an in-house exome capture platform, VCRome version 2.1 (targeting ≈20 000 genes, including the coding and untranslated region exons), was sequenced using a HiSeq. This platform has a minimum depth of coverage of 20× with a practical detection rate of ≈95% of all single-nucleotide variants and insertion/deletions. Samples were additionally analyzed by an Illumina HumanExome-12 v1 cSNP array for quality control assessment of exome data, as well as for detecting large copy-number variants and regions of absence of heterozygosity.
Nomenclature
Missense variants were defined as those that altered a single amino acid. Radical mutations were defined as variants that are predicted to cause more than a single amino acid change, including nonsense (early termination), insertion/deletion (both in-frame and out-offrame), and predicted canonical splice site mutations. Pathological, likely pathological, or VUS was based on the designation ascribed by the WES test.
Primary Sequence Localization
Variant localization was conducted using the RYR2 consensus sequence from Ensembl browser. 11 Specifically, the RyR2 (NP_001026.2)
WHAT IS KNOWN
• Pathogenic mutations in RYR2 and CASQ2 are associated with the development of catecholaminergic polymorphic ventricular tachycardia (CPVT), a sudden death predisposing arrhythmia.
• Rapid expansion of genetic testing technologies has increased the utilization of clinical whole-exome sequencing (WES) and, with it, the incidental identification of VUSs in RYR2 and CASQ2.
WHAT THE STUDY ADDS
• Clinically reported incidentally identified variants in RYR2 and CASQ2 are found in ≈9% of WES tests.
• The location of WES-identified variants more closely resembles healthy variation than pathogenic mutations.
• For those WES referral subjects who underwent cardiac evaluation with a low pretest suspicion for channelopathic disease, there was no clinical evidence of CPVT. 
Statistics
Results
Prevalence of RYR2 and CASQ2 Variants in the WES Cohort
To establish the background rate of RYR2 and CASQ2 variants, a large cohort of clinical whole-exome genetic testing referrals was interrogated. The clinical whole-exome cohort consisted of 6517 individuals, derived from 6477 families, with 3529 male (54.2%), 2941 female (45.1%), and 47 (0.7%) fetal subjects ( Figure 1A ; 
Gene-Specific Variant Prevalence
To determine the gene-specific prevalence of variants in RYR2 and CASQ2 and the number of variants deemed likely pathological or VUS for each gene, subset analysis of the variants was conducted. 
Mutation Class-Specific Variant Prevalence
To determine the prevalence of radical and missense mutations among the WES cohort, subset analysis of the variants based on mutation class was conducted. .0]) between RYR2 and CASQ2, respectively. These results are summarized in Figure 3 .
Comparison of WES Cohort Prevalence Versus CPVT Cases and Healthy Controls
To compare the RYR2 and CASQ2-associated rare variant frequency among the WES cohort and known CPVT cases, a compendium of CPVT-associated mutations was used. 8 8, 12 The prevalence of mutation-positive individuals in robust CPVT cases was over 6-fold higher than the 8.8% of individuals hosting RYR2 and CASQ2 variants among the clinical WES cohort (P<0.0001). To compare the variant frequency between the WES cohort and healthy individuals, the frequency of variants with a minor allele frequency <0.01 among ostensibly healthy control subjects was analyzed. Among these individuals, the rate of RYR2 and CASQ2 variants was 6.0% [5.8-6 .2] which was statistically lower than the 8.8% prevalence among the clinical WES cohort (P<0.0001).
The higher rate of CPVT case variants was driven by a higher prevalence of missense variants. Figure 4 .
Variant Colocalization Between Cohorts and Mutation Hotspots
To determine whether variants identified among the clinical WES cohort more frequently altered amino acids affected by control or case variants, we next mapped each of the variants along the primary sequence of RyR2. Variants identified in the WES cohort localized to 278 individual RyR2 residues, whereas case and control variants localized to 140 and 973 individual residues, respectively. There was a background level of overlap between these 3 cohorts with 41 RyR2 Figure 5 .
Classically, RyR2 variants have clustered to mutation hotspots within RyR2; however, recently expanded genetic studies have identified several putatively disease-associated variants that are located outside of these regions. Among CPVT cases, 80.2% [72.3-86.6] of mutated residues were located within 1 of 3 canonical mutation hotspots, whereas 32.2% [29. .3] of altered residues among control cohort individuals localized to a hotspot (P<0.0001). Among WES cohort individuals, 10.5% [8.6-12.6 ] of altered residuals located within a canonical hotspot which was significantly less than both case and control variants (P<0.0001, respectively).
Further, WES cohort variants seemed to be distributed across the linear topology of RyR2 without apparent clustering in a manner similar to control variants. These findings are depicted in Figure 6 .
Pretest Clinical Suspicion of CPVT Among WES Referrals
To evaluate whether children referred for WES genetic testing demonstrated pre-WES suspicion for CPVT, or a post-test diagnosis of CPVT other occult channelopathic arrhythmias, we evaluated the WES referrals from our institution (TCH). A total of 140 individual probands from 136 families were identified who were referred for WES testing and who hosted either likely pathological or VUSs of RYR2 and CASQ2. The median age of this cohort was 5.5 years [2.1-9.2] at the time of genetic testing with a range of 0.01 to 52.0 years. Seventyfour (52.9%) were male, 66 (47.1%) female, 18 (12.9%) Black/African, 7 (5.0%) Asian American/Asian, 46 (32.5%) White/Non-Hispanic, and 69 (49.6%) were Hispanic. The results are summarized in Table 2 .
In this subgroup, the indication for genetic testing was concern for cardiovascular disease in only a small minority of referrals. Within the TCH cohort, 85.7% of the cohort was referred for WES because of neurological disease with 66.4% having a referral of developmental delay and 16.4% with abnormal muscular tone. About 27.1% of referrals had an indication of seizures or epilepsy; however, only 1.4% of the cohort had this as the sole indication for genetic testing. About 12.9% of the WES cohort carried an indication of cardiac disease as any part of the clinical phenotype. About 5% of the cohort was referred for solely cardiovascular disease diagnoses, and all cardiovascular only referrals were for structural cardiac disease or concern for cardiomyopathy with the exception of a single referral with a structurally normal heart. This individual also had a history of syncope and a family history of sudden cardiac death and was ultimately found to have a RyR2-G3946S mutation identified as likely pathogenic by WES (detailed below). With the exception of this individual, no other subject had family history of sudden death (99.3% negative [96.1-100]), and only one other had a personal history of syncope (98.5% negative [94.9-99.8]). None had a history of clinical CPVT. Taken together, these findings suggest a low pre-WES testing concern for CPVT among 
Clinical Evaluation of WES Cohort Referrals With CPVT-Associated Variants
To determine whether WES referrals incidentally found to host RYR2 and CASQ2 variants had clinical evidence of CPVT, the available initial cardiac evaluation and subsequent visits for the TCH cohort were reviewed. ECG, 24-hour Holter, and treadmill stress tests were reviewed for presence of ventricular ectopy (PVCs) or VT. Among those evaluated, 2 (1.4%) individuals had evidence of ventricular ectopy. One individual, a 4-year-old male with macrocephaly, hemimegalencephaly, and capillary malformations with resultant severe developmental delay, had frequent PVCs. WES analysis for this constellation demonstrated a RAB23 mutation that was felt to be pathological and numerous VUSs, including RyR2-R3190Q. Multiple 24 Holters confirmed frequent PVCs without evidence of VT or CPVT. The second individual found to have ventricular ectopy was a 7-year-old male who initially presented with syncope and had a family history of sudden death mentioned previously. He was found to have a structurally normal heart. ECG demonstrated normal sinus rhythm with a normal QTc, and a treadmill stress testing demonstrated PVCs. He has no history of VT with exercise or at rest. WES analysis demonstrated a RyR2-G3946S variant. He holds a diagnosis of possible CPVT. One-hundred and thirty-eight (98.6% [94.9-99.8]) individuals had no clinical evidence of ventricular ectopy and no clinical evidence of CPVT. These results are summarized in Figure 7C .
To evaluate for the presence of additional signs/symptoms of CPVT, we evaluated the subjects in the TCH cohort for history of syncope or a family history of sudden death. Two 
Discussion
Paramount to the interpretation of any clinical test is an understanding of the spectrum of healthy variation. Because the field of genetic testing, and the science behind genomic sequencing, has rapidly advanced, the ability to genetically interrogate individuals with clinical disease has rapidly outstripped our knowledge of the genetic background in the healthy population. 13 This has led to significant confusion over what clinical risk incidentally identified variants may confer, particularly variants that are not clearly linked to disease. Compounding this is the recommendation by the American College of Medical Genetics and Genomics to report any known pathological variant associated with CPVT that is incidentally found.
14 Although early studies have demonstrated the spectrum and prevalence of rare background variation in cardiomyopathic diseases, such as hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy, as well as channelopathic diseases, such as long QT syndrome, CPVT has lagged behind. [15] [16] [17] Our finding that ≈9% of individuals undergoing clinical WES will have a variant of either undetermined significance or deemed likely pathological that is eligible for clinical reporting highlights this problem. In the postgenomic era of science and medicine, the challenge has shifted away from developing genetic sequencing techniques to the clinical interpretation of the findings.
Classically, the interpretation of a genetic test result, or any other clinical test, has been done in the context of pretest clinical suspicion. Higher diagnostic value may be placed on a VUS in the setting of proband with a high suspicion for clinical disease with a positive family history and cosegregation of that variant with incidence of disease in the family. Conversely, lower diagnostic value may be placed on a variant identified in an individual who has low clinical suspicion of disease. Although ≈9% of individuals among the clinical WES cohort were positive for variants, a small minority of the referrals from our institution had clinical suspicion for occult channelopathic disease. Indeed, slightly <90% of the referral cohort was sent for genetic testing because of neurological disease, and only 5% had cardiac disease as the sole indication for genetic testing. Among these cardiac only referrals, only 1 patient had a structurally normal heart and a personal history concerning for channelopathic disease. Interestingly, the only subject to demonstrate any evidence of ventricular ectopy and may hold a diagnosis of CPVT is the individual with a high pre-WES clinical suspicion for occult channelopathy.
In an attempt to broadly guide interpretation of genetic testing findings, the American College of Medical Genetics and Genomics has published guidelines for classifying a variety of genetic variants along the spectrum of pathogenicity. 18 Within these guidelines is recognition that variant colocalization to an amino acid residue previously shown to contain a known pathological mutation is associated with a higher risk of pathogenicity. We find that there is overlap between the variant location of RyR2 variants associated with control individuals and CPVT cases with a notable 29% of variants in cases overlapping with residues with healthy variants. Conversely, 4% of variants found in healthy individuals genetically overlap with cases, implying inherent risk of overcalling the pathogenicity of healthy variation if indiscriminately applied. We also find that there is significant overlap in the WES variants and healthy individuals, 60%, which is significantly higher than with CPVT cases (8%). These support the conclusion that WES-identified variants are less likely to represent biomarkers of disease predisposition. At the same time, there remains many WES variants which, even in the context of a low clinical suspicion, may be ascribed elevated pathological status based solely on variant location or type. As such, caution should be given to ascribing increased likelihood of pathogenicity based solely on an incidentally identified variant in the absence of clinical suspicion for disease. 19 Signs and symptoms of CPVT most often manifest in childhood. In a cohort-based study of CPVT, the first syncopal event occurred at a mean of ≈7.8 years with a diagnosis made at a mean age of ≈10 years. Further, approximately one third of CPVT patients had a family history of syncope or sudden death. 20 By nature of a demographic referral bias, we find that the subjects comprising the TCH cohort are youthful with a mean age of ≈6.6±6.3 years. Clinical evaluation for syncope, heritable sudden death, or ventricular ectopy identified a single individual with clinical suspicion for CPVT. Although we find that subjects with incidentally identified CPVT-associated variants demonstrate a low index of suspicion for occult channelopathic disease, we cannot exclude the possibility that clinical manifestations of CPVT may develop later in life.
There is recent evidence implicating RYR2 mutations in the development of seizures, epilepsy, and sudden death in epilepsy. 21 Interestingly, although the majority of individuals referred for WES testing had a neurological diagnosis, epilepsy/seizures as the sole indication was rare (≈1.4%). While limited by the documentation sent by the referring provider, these findings support the conclusion that incidentally identified RYR2 variants are not common among individuals with a sole referral diagnosis of seizures or epilepsy. In addition, several studies have linked mutations in RYR2 to the development 22 It is possible that some of these variants may represent susceptibility alleles for the development of cardiomyopathy in certain individuals.
Traditionally, CPVT-associated variants localizing to RYR2 are missense mutations affecting a single amino acid, although the functional impact of radical mutations and their association with arrhythmia development are not well defined. We observe a low frequency of radical mutations among CPVT cases (2.6%) with a statistically similar frequency among control (0.9%) and WES (1.6%) subjects. In contrast, radical mutations in genes encoding the cardiac sarcomere and cardiac desmosome lead to a high likelihood of pathogenicity in hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy, respectively. 16, 17 One possibility is that this divergence represents an intolerance of the cardiomyocyte to loss-of-function mutations in large structural and mechanical proteins resulting in pathological myocardial remodeling, although there may be expression compensation of the wild-type RYR2 allele preventing CPVT. Additional investigation will be needed to determine the functional impact of these radical RYR2 variants. Conversely, CPVT-associated CASQ2 mutations are inherited in an autosomal recessive fashion and cause disease when homozygous. We identified only a single individual hosting a homozygous CASQ2 mutation, suggesting that the vast majority of variants within the WES cohort were variants with a presumed autosomal dominant inheritance pattern. Overall, this supports the conclusion that these variants either reflect potential unaffected genetic carriers or do not reflect a mode of inheritance which is classically associated with CPVT pathogenesis.
We observe that the background rare variant rate among ostensibly healthy volunteers is 6.0% which is similar to the background variant rate identified in long QT syndrome (≈5%) and hypertrophic cardiomyopathy (≈5%) and is significantly lower than the background rate of the arrhythmogenic right ventricular cardiomyopathy genetic test (≈16%). [15] [16] [17] This observed frequency is slightly lower than a previous estimate of CPVT background variation on a more limited cohort of ostensibly healthy individuals within the National Heart, Lung, and Blood Institute Exome Sequencing Project of ≈11%. 23 Given the observed yield of likely pathogenic mutations in 60% of individuals with phenotypically robust CPVT, this gives a signal:noise ratio of ≈10:1. This ratio is similar to long QT syndrome (≈15:1) and hypertrophic cardiomyopathy (≈12:1) which underscores the diagnostic use of the CPVT genetic test despite the background rate of genetic variation. 24 Given the high yield of CPVT genetic testing and the high signal:noise ratio, the targeted gene testing (ie, CPVT gene panel testing) remains the optimal diagnostic genetic testing tool. In this way, WES testing during the diagnostic evaluation of patient with suspected CPVT is unlikely to provide additional diagnostic use as an initial genetic testing platform.
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